LY 3532226
Alternative Names: LY-3532226Latest Information Update: 01 Apr 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Feb 2024 Eli Lilly and Company completes a phase I trial in Type 1 diabetes mellitus in USA (SC) (NCT05887999)
- 12 Jan 2024 Eli Lilly completes a phase I trial in Type 2 diabetes mellitus (Combination therapy) in Germany (SC) (NCT05407961)
- 12 Jun 2023 Phase-I clinical trials in Type 1 diabetes mellitus in USA (SC) (NCT05887999)